eligibility_summary
Adults (≥18) with unresectable/metastatic gastric/GEJ adenocarcinoma, tumor tissue, CLDN18.2+ for expansion, ECOG 0–1, progressed/intolerant/no standard therapy, measurable extracranial lesion. Prior lines: escalation no limit, mono 1–3L, ramu: 1 prior line incl fluoropyrimidine+platinum, dostarlimab: no prior systemic tx. Excl: pregnant/lactating, brain mets, prior CLDN18.2/auristatin ADC, ≥G2 neuropathy/ILD/ocular/gastritis, major cardiac disease, HER2+, prior ramu/VEGFR2, prior ICI.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1 trial testing: 1) EO-3021: an anti-CLDN18.2 antibody–drug conjugate (ADC). Mechanism: binds claudin 18.2 on tumor cells, is internalized, and delivers a cytotoxic payload to kill CLDN18.2-expressing cells. Drug type: targeted ADC. 2) Ramucirumab (CYRAMZA): monoclonal antibody VEGFR2 inhibitor. Mechanism: blocks VEGF–VEGFR2 signaling to suppress tumor angiogenesis. Drug type: anti-angiogenic mAb. 3) Dostarlimab: anti–PD-1 monoclonal antibody. Mechanism: blocks PD-1 to relieve T-cell inhibition and boost antitumor immunity. Drug type: immune checkpoint inhibitor mAb. Target cells/pathways: CLDN18.2+ gastric/GEJ adenocarcinoma cells (ADC-mediated cytotoxicity), VEGFR2 pathway in tumor endothelium (angiogenesis), and PD-1 checkpoint on T cells (immune activation).